SynthesisJournal of the American Academy of Orthopaedic Surgeons. Global research & reviews2020
Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease.
Synthesis in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Knowledge map of recurrence in tenosynovial giant cell tumor: a bibliometric analysis.Frontiers in oncology · 2025Pooled it
- Arthroscopic Versus Open Management of Diffuse-Type Tenosynovial Giant Cell Tumor of the Knee: A Meta-analysis of Retrospective Cohort Studies.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2021Pooled it
- Pooled it
- Trial
- Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet (London, England) · 2024Trial
- Localized Tenosynovial Giant Cell Tumors and Indicators of Surgical Recurrence.Journal of hand surgery global online · 2026Article
- Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors.Cancer metastasis reviews · 2026Review
- A Phase 3 Study of the Efficacy and Safety of Pexidartinib in East Asian Patients with Tenosynovial Giant Cell Tumor.Oncology and therapy · 2025Article
- Tenosynovial Giant Cell Tumors in the Hand and Foot.Cureus · 2025Article
- Diffuse-Type Tenosynovial Giant Cell Tumor of the Knee: Clinical Course After Anterior Open Synovectomy.Current oncology (Toronto, Ont.) · 2025Article
- Tenosynovial Giant Cell Tumor Involving Quadriceps Muscle - A Case Report of Two Cases.Journal of orthopaedic case reports · 2025Article
- Novel Clinical Practice Assessments: Informational Statements by the Musculoskeletal Tumor Society.Journal of surgical oncology · 2025Review
- Deciphering T Cell Dynamics in Alzheimer's Disease Pathogenesis: Insights and Implications.Current neuropharmacology · 2025Review
- Pexidartinib Upfront in a Case of Tenosynovial Giant Cell Tumor: Proof of Concept for a Treatment Paradigm Shift.Oncology and therapy · 2024Article
- Tenosynovial Giant Cell Tumor in the Gruberi BursaBalkan medical journal · 2024Article
- Endoscopic En Bloc Resection of Giant Cell Tumor of Tendon Sheath of Anterior Ankle.Arthroscopy techniques · 2024Article
- Giant cell tumor of distal radius: En bloc resection with allograft reconstruction: A case report.Clinical case reports · 2024Article
- Diffuse-Type Tenosynovial Giant Cell Tumor: What Are the Important Findings on the Initial and Follow-Up MRI?Cancers · 2024Review
- TURALIOFuture oncology (London, England) · 2024Article
- Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies.The oncologist · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
Abstract
backgroundPatients with diffuse tenosynovial giant cell tumor (TGCT) face a high risk of recurrence, progression, and disability. This systematic review assesses the recent evidence of surgical, adjuvant, and systemic treatments for TGCT.
methodsWe searched PubMed and Ovid with the terms "Giant cell tumor of tendon sheath" OR "pigmented villonodular synovitis" OR "tenosynovial giant cell" AND "treatment" OR "surgery." INCLUSION CRITERIA: published 2013 to present; prospective or retrospective design; English language; > 20 patients with histopathological confirmed diagnosis of TGCT; and ≥ 1 efficacy and/or safety outcome from surgery, systemic drug therapy, or adjuvant yttrium radiosynoviorthesis.
resultsOf the 434 studies identified, 25 met the inclusion criteria. Of 11 studies in patients with disease in the knee, nine examined surgical treatment approaches, and two evaluated adjuvant yttrium radiosynoviorthesis. Of 11 studies in patients with mixed sites of disease, six assessed surgical treatment approaches, and five evaluated systemic drug therapies. Three studies assessed surgery in patients with TGCT in the hand, hip, and ankle or foot. DISCUSSION: The high rates of recurrence and risks associated with surgery emphasize the need for novel treatments in patients with symptomatic, advanced TGCT. Systemic therapy may be valuable as part of a multidisciplinary approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.